Brief: Solid Biosciences Patient Dosing Expected To Begin Mid-To-Late Q1 2024
16/01/2024 13:05
Jan 16 (Reuters) - Solid Biosciences Inc SLDB.O :
* SOLID BIOSCIENCES GRANTED FDA ORPHAN DRUG DESIGNATION FOR
DUCHENNE MUSCULAR DYSTROPHY GENE THERAPY CANDIDATE SGT-003
* SOLID BIOSCIENCES INC - PATIENT DOSING EXPECTED TO BEGIN
MID-TO-LATE Q1 2024
Source text for Eikon: ID:nGNX8CnnlV
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs